- RxCelerate has helped Morphogen-IX to transition its research activities to a fully integrated drug development programme with a clear strategy to increase asset value and demonstrate clinical proof-of-concept.
- In partnership with the founders of Morphogen-IX, RxCelerate has developed bespoke preclinical models and generated key mechanistic data to support selection of the clinical candidate.
- RxCelerate has responsibility for managing company operations and budget, collaborations and out-sourced drug development activities.
RxCelerate has undertaken the preclinical development of Morphogen-IX's exciting new asset targeting the underlying disease pathology in pulmonary arterial hypertension. As a consequence of the critical evaluation of experimental models by Jill and her team, we developed a much deeper understanding of the key preclinical endpoints that are likely to translate into reversal of human pathology. This was a partnership in which RxCelerate showed the ability to question prevailing dogma to make a major difference to our drug development programme. The delivery and execution of preclinical studies has been first-class. I cannot recommend them highly enough if you need to build confidence and proof-of-concept in your preclinical programmes.